Launched in 2021 and based in Gurugram, Wholeleaf develops medically oriented natural pain therapeutics, leading the cannabinoid pain therapeutics category in India. Its portfolio includes oral tinctures and topical formulations addressing migraines, arthritis, fibromyalgia, menstrual pain, anxiety, and sleeplessness, and it is building a pipeline focused on chronic neuropathic pain. The company uses a physician-led, multi-stage product validation process that includes safety testing, pilot studies, and third-party government-certified laboratory assessments. Wholeleaf claims presence across nearly 2,000 retail outlets—primarily in the Delhi-NCR region—and plans to expand to 5,000–7,000 outlets within the year, targeting deeper penetration in tier I and tier II cities such as Bengaluru, Mumbai, Hyderabad, Kolkata, Ahmedabad, Goa and Chennai. The company reports an ARR of Rs 18 crore and intends to deploy new funding to expand retail presence, strengthen product development, scale distribution, and enhance brand visibility.

Total raised

$0M

Funding rounds

1

Latest round

Seed

Latest activity

Feb 2026